Trial Profile
A Comparison of Standard Vs Renal Dosing of Piperacillin/Tazobactam in Acute Renal Failure and Septic Shock.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 16 Sep 2015
Price :
$35
*
At a glance
- Drugs Piperacillin/tazobactam (Primary)
- Indications Bacterial infections; Septic shock
- Focus Therapeutic Use
- 11 Sep 2015 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 01 Jul 2010 Planned end date changed from 1 Jun 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.
- 01 Jul 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.